Cargando…
Clozapine N-Oxide Administration Produces Behavioral Effects in Long–Evans Rats: Implications for Designing DREADD Experiments
Clozapine N-oxide (CNO) is a ligand for a powerful chemogenetic system that can selectively inhibit or activate neurons; the so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADD) system. This system consists of synthetic G-protein-coupled receptors, which are not believed to...
Autores principales: | MacLaren, Duncan A. A., Browne, Richard W., Shaw, Jessica K., Krishnan Radhakrishnan, Sandhya, Khare, Prachi, España, Rodrigo A., Clark, Stewart D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089539/ https://www.ncbi.nlm.nih.gov/pubmed/27822508 http://dx.doi.org/10.1523/ENEURO.0219-16.2016 |
Ejemplares similares
-
The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice
por: Manvich, Daniel F., et al.
Publicado: (2018) -
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
por: Jendryka, Martin, et al.
Publicado: (2019) -
DREADD-Induced Silencing of the Medial Olfactory Tubercle Disrupts the Preference of Female Mice for Opposite-Sex Chemosignals
por: DiBenedictis, Brett T., et al.
Publicado: (2015) -
Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs
por: van der Peet, Phillip L., et al.
Publicado: (2018) -
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based
DREADDs in Vitro and in Vivo
por: Thompson, Karen J., et al.
Publicado: (2018)